March 5, 2024 – Last night, the results of the first large-scale study involving a bi-hormonal fully closed-loop system with individuals with type 1 diabetes were published, presenting the outcomes of the Inreda AP®. Over 70 individuals used the Inreda AP® for a period of 1 year. The results have been analysed by researchers and published by The Lancet Digital Health, one of the leading scientific journals. We are pleased to provide further details regarding the study and its results!
The aim of the study was to gather long-term data on the Inreda AP® concerning glucose outcomes, safety, and the experiences of individuals with type 1 diabetes. The entire study was conducted in a home setting without any constraints, allowing us to collect the representative data during daily life. A total of 79 individuals from 8 different hospitals in the Netherlands participated in the study, and these results are now published by The Lancet Digital Health.
The primary outcome was the time spent in the target range (Time in Range), which significantly improved from 55.5% to 80.3%! This signifies that Inreda AP® users spend, on average, 6 hours longer per day within healthy target ranges compared to their previous therapy. This can yield numerous benefits, as the longer someone stays within healthy target ranges, the lower the risk of short- and long-term complications. Additionally, the quality of life improved during the use of the Inreda AP®.
Blood glucose regulation is fully automatic, allowing individuals to better manage their diabetes. We asked study participants about their experience of diabetes burden using a questionnaire (PAID). At the beginning of the study, the group of participants rated the diabetes burden with a score of 30, which decreased to a score of 10 after 12 months. It is important to note: the lower the score, the less burden is experienced from diabetes. This score has significantly decreased as well!
We are very proud of these results, as they represent a significant breakthrough in the field of diabetes. Haven’t had enough yet? Read more about the study in our factsheet:
Additionally, if you want more information or wish to read the complete publication, you can access the article published by The Lancet Digital Health.
Furthermore, we would like to thank all Inreda AP® users and researchers who contributed to this research; without your involvement, this achievement would not have been possible. Additionally, we would like to thank the health insurance Menzis for providing coverage of the Inreda AP® treatment during the study. Menzis has also made it possible for people to continue the treatment even after the study!
